The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin

Diabetes Care

Volumn 35, Issue 4, 2012, Pages 690-692

  Cengiz, Eda ^a   Swan, Karena L ^a   Tamborlane, William V ^a   Sherr, Jennifer L ^a   Martin, Melody ^a   Weinzimer, Stuart A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN ASPART; INSULIN DETEMIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG INHIBITION; DRUG MIXTURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS; INSULIN ASPART; INSULIN, LONG-ACTING; MALE; TIME FACTORS; YOUNG ADULT;

EID: 84862091465     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0732     Document Type: Article

References (10)

1. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004;21:1498-1504 (Pubitemid 39149667)
2. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-649 (Pubitemid 30321545)
3. Fiallo-Scharer R, Horner B, McFann K, Walravens P, Chase HP. Mixing rapid-acting insulin analogues with insulin glargine in children with type 1 diabetes mellitus. J Pediatr 2006;148:481-484
4. Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Pediatrics 2008;121:e466-e472
5. Nguyen TM, Renukuntla VS, Heptulla RA. Mixing insulin aspart with detemir does not affect glucose excursion in children with type 1 diabetes. Diabetes Care 2010;33:1750-1752
6. Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care 2010;33:1009-1012
7. Swan KL, Dziura JD, Steil GM, et al. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care 2009;32:240-244
8. Swan KL, Weinzimer SA, Dziura JD, et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabetes Care 2008;31:44-46
9. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223 (Pubitemid 9249478)
10. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28:1107-1112 (Pubitemid 40616620)